Drug Profile
Research programme: ion channel antibody therapeutics - Pfizer
Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Tetragenetics
- Class Antibodies
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 13 Sep 2021 Tetragenetics has been acquired by Abcellera
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 03 Apr 2013 Early research in Undefined indication in USA (unspecified route)